The TrumpRx program, touted for its potential to offer lower prescription drug prices, is experiencing significant setbacks just a month after its launch. Despite being highlighted in a recent State of the Union address and promising discounts on popular medications, reports indicate that the initiative has fallen short of the grand claims made by its supporters. Legal ambiguities and scrutiny from the Senate have cast doubts over its viability, with experts suggesting the possibility of increased anti-kickback violations. Additionally, Democrats from the House Energy and Commerce Committee have published a report reflecting on the shortcomings of the program. As the initiative struggles to gain traction, concerns over limited savings for insured individuals due to U.S. discount laws further complicate its implementation and future prospects.